Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2003 1
2004 2
2005 2
2006 3
2007 2
2008 1
2009 5
2010 4
2012 2
2013 4
2014 8
2015 5
2016 2
2017 4
2018 7
2019 7
2020 5
2021 6
2022 3
2023 8
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

79 results

Results by year

Filters applied: . Clear all
Page 1
Enthesitis: from pathophysiology to treatment.
Schett G, Lories RJ, D'Agostino MA, Elewaut D, Kirkham B, Soriano ER, McGonagle D. Schett G, et al. Among authors: kirkham b. Nat Rev Rheumatol. 2017 Nov 21;13(12):731-741. doi: 10.1038/nrrheum.2017.188. Nat Rev Rheumatol. 2017. PMID: 29158573 Review.
Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial.
McInnes IB, Mease PJ, Kirkham B, Kavanaugh A, Ritchlin CT, Rahman P, van der Heijde D, Landewé R, Conaghan PG, Gottlieb AB, Richards H, Pricop L, Ligozio G, Patekar M, Mpofu S; FUTURE 2 Study Group. McInnes IB, et al. Among authors: kirkham b. Lancet. 2015 Sep 19;386(9999):1137-46. doi: 10.1016/S0140-6736(15)61134-5. Epub 2015 Jun 28. Lancet. 2015. PMID: 26135703 Free article. Clinical Trial.
Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial.
Nash P, Kirkham B, Okada M, Rahman P, Combe B, Burmester GR, Adams DH, Kerr L, Lee C, Shuler CL, Genovese M; SPIRIT-P2 Study Group. Nash P, et al. Among authors: kirkham b. Lancet. 2017 Jun 10;389(10086):2317-2327. doi: 10.1016/S0140-6736(17)31429-0. Epub 2017 May 24. Lancet. 2017. PMID: 28551073 Clinical Trial.
IL-17 in the immunopathogenesis of spondyloarthritis.
Taams LS, Steel KJA, Srenathan U, Burns LA, Kirkham BW. Taams LS, et al. Among authors: kirkham bw. Nat Rev Rheumatol. 2018 Aug;14(8):453-466. doi: 10.1038/s41584-018-0044-2. Nat Rev Rheumatol. 2018. PMID: 30006601 Review.
A new era for collaboration?
Packham JC, Abraham S, Kirkham B, Helliwell P, Siebert S, Korendowych E, Fitzgerald O, Parkinson A, Brookes M, Coates L, McHugh N. Packham JC, et al. Among authors: kirkham b. Rheumatology (Oxford). 2018 May 1;57(5):775-776. doi: 10.1093/rheumatology/kex083. Rheumatology (Oxford). 2018. PMID: 28407115 No abstract available.
Rheumatoid Arthritis - Anti-TNF.
Chaabo K, Kirkham B. Chaabo K, et al. Among authors: kirkham b. Int Immunopharmacol. 2015 Aug;27(2):180-4. doi: 10.1016/j.intimp.2015.04.051. Epub 2015 May 8. Int Immunopharmacol. 2015. PMID: 25962818 Review.
BiTE therapy for rheumatoid arthritis.
Humby F, Kirkham B, Taams L. Humby F, et al. Among authors: kirkham b. Nat Med. 2024 May 8. doi: 10.1038/s41591-024-02982-z. Online ahead of print. Nat Med. 2024. PMID: 38720000 No abstract available.
79 results